{"id":296426,"date":"2022-04-18T00:00:00","date_gmt":"2022-04-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0030-2022-biopharma-multiple-sclerosis-unmet-need-unmet-need-relapsing-forms-of-multiple\/"},"modified":"2026-03-31T10:39:46","modified_gmt":"2026-03-31T10:39:46","slug":"unnecg0030-2022-biopharma-multiple-sclerosis-unmet-need-unmet-need-relapsing-forms-of-multiple-sclerosis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0030-2022-biopharma-multiple-sclerosis-unmet-need-unmet-need-relapsing-forms-of-multiple-sclerosis-us-eu\/","title":{"rendered":"Multiple Sclerosis &#8211; Unmet Need &#8211; Unmet Need &#8211; Relapsing Forms of Multiple Sclerosis (US\/EU)"},"content":{"rendered":"<p>An increasing number of clinically unique immunomodulatory disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) are approved for the treatment of relapsing forms of multiple sclerosis (<abbr title=\"multiple sclerosis\">MS<\/abbr>), the most prevalent form of <abbr title=\"multiple sclerosis\">MS<\/abbr>. Nevertheless, all approved drugs give way to clinical shortcomings in terms of efficacy, safety, tolerability, and\/or delivery, creating opportunities for new and improved <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s, be they next-in-class or pioneering. This content provides quantitative insight into U.S. and European physicians\u2019 perceptions of key treatment drivers and goals in the management of relapsing forms of <abbr title=\"multiple sclerosis\">MS<\/abbr> and the current level of unmet need in this area. We analyze the commercial opportunities and how new \/ emerging novel and next-generation compounds may capitalize on these opportunities in our conjoint-based Target Product Profile simulator.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for relapsing forms of <abbr title=\"multiple sclerosis\">MS<\/abbr>?<\/li>\n<li>What drug attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for relapsing forms of <abbr title=\"multiple sclerosis\">MS<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in relapsing forms of <abbr title=\"multiple sclerosis\">MS<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for relapsing forms of <abbr title=\"multiple sclerosis\">MS<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 63 U.S. and 31 European neurologists fielded in February 2022<\/p>\n<p><strong>Key companies:<\/strong> Novartis, Sanofi Genzyme, Biogen, Merck KGaA, Teva,\u00a0Roche \/ Genentech<\/p>\n<p><strong>Key drugs:<\/strong> Gilenya, Aubagio, Tecfidera \/ dimethyl fumarate, Mavenclad, Copaxone \/ glatiramer acetate, Tysabri, Ocrevus<\/p>\n","protected":false},"template":"","class_list":["post-296426","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296426\/revisions"}],"predecessor-version":[{"id":296643,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296426\/revisions\/296643"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}